Trial reportJournal of clinical laboratory analysis2007
Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.
Trial report in Journal of clinical laboratory analysis, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Blood biomarkers for the non-invasive diagnosis of endometriosis.The Cochrane database of systematic reviews · 2016Pooled it
- Elevated serum chromogranin A levels are independently associated with metabolic and inflammatory disturbances in polycystic ovary syndrome.Frontiers in endocrinology · 2025Article
- Development and Validation of a Nomogram to Predict the Risk of Special Uterine Leiomyoma Pathological Types or Leiomyosarcoma in Postmenopausal Women: A Retrospective Study.Risk management and healthcare policy · 2024Article
- Benign metastasising leiomyoma: a rare disease and a diagnostic challenge.BMJ case reports · 2022Article
- Abdominopelvic leiomyoma with large ascites: A case report and review of the literature.World journal of clinical cases · 2021Article
- Article
- High-soluble CGA levels are associated with poor survival in bladder cancer.Endocrine connections · 2019Article
- Adnexal mass with extremely high levels of CA-125 and CA19-9 but normal Human Epididymis Protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA): Endometriosis or ovarian malignancy? A case report.International journal of reproductive biomedicine · 2018Article
- Tumor characterization by ultrasound-release of multiple protein and microRNA biomarkers, preclinical and clinical evidence.PloS one · 2018Article
- Uterine fibroids with positive 18F-FDG PET/CT image and significantly increased CA19-9: A case report.Medicine · 2017Article
- Elevated serum CA 19-9 at screening tests: underlying conditions and role of abdominopelvic CT.European radiology · 2014Article
- CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics.International journal of clinical and experimental medicine · 2014Article
- Biomarkers in uterine leiomyoma.Fertility and sterility · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As the best-known tumor marker for ovarian carcinoma, CA 125 has also been commonly used to monitor patients with common benign gynecologic diseases such as endometriosis and leiomyoma. Both of these benign tumors are known to be at risk of developing into cancer. During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both. In addition to the detection of elevation of CA 125 in these benign tumors, elevated CA 19-9 or CgA was also found in these patients with endometriosis or leiomyoma. Many patients only had elevated CA 19-9 or CgA; the elevation of CA 125 was not detected. It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.